Stockscreener 앱 받기
28.20
0.19%
-0.055
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences Inc (RCUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Three new Arcus employees receive options and 6,300 restricted stock units - Stock Titan
RCUS|Arcus Biosciences Inc|Price:27.850|Chg%:-0.570 - TradingKey
Arcus Biosciences Inc (RCUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcus Biosciences Inc (RCUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Arcus Biosciences Inc (RCUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Price to earnings forward of Arcus Biosciences, Inc. – NYSE:RCUS - TradingView
Price to sales forward of Arcus Biosciences, Inc. – NYSE:RCUS - TradingView
RCUS|Arcus Biosciences Inc|Price:28.430|Chg%:-1.300 - TradingKey
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
ETFs Investing in Arcus Biosciences, Inc. Stocks - TradingView
Arcus: 'Buy' Casdatifan Late-Stage ccRCC Advancement And 1st-Line Expansions (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences Inc (RCUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $41 - Moomoo
H.C. Wainwright reiterates Arcus Biosciences stock rating at buy By Investing.com - Investing.com Canada
Why Did Arcus Biosciences (NYSE:RCUS) Announce New Trial? - Kalkine Media
Arcus Biosciences (RCUS) Partners with Summit Therapeutics for K - GuruFocus
Arcus Biosciences (RCUS) Forms Clinical Supply Agreement with AV - GuruFocus
Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration - TradingView
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - marketscreener.com
Arcus Biosciences to host Q2 2026 financial results call - scanx.trade
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5 - Stock Titan
(RCUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? - Benzinga
Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy - AlphaStreet
RCUS Maintained by HC Wainwright & Co. -- Price Target Raised to $45 - GuruFocus
H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.com - Investing.com Canada
Arcus Biosciences (RCUS) Proxy filing Summary - Quartr
This Insider Has Just Sold Shares In Arcus Biosciences - simplywall.st
Arcus Biosciences President Sells 68,569 Shares in July 2026 - sekbernews.id
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run - The Motley Fool
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run - The Motley Fool
Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 plan - Stock Titan
Arcus Biosciences president Juan C. Jaen sells $2.03m in shares - Investing.com Canada
Form 4 Arcus Biosciences Inc For: 13 July By Investing.com - Investing.com UK
Form 144 Arcus Biosciences For: 9 July By Investing.com - Investing.com Nigeria
Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts - Stock Titan
Arcus Biosciences awards stock options to five new employees - Stock Titan
Arcus Biosciences grants options and RSUs to new employees - scanx.trade
Arcus Biosciences (RCUS) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - AOL.com
Arcus Biosciences Announces New Employment Inducement Grants - AOL.com
Arcus Biosciences (RCUS) Surges 4.88% as Shares Test Key Resistance LevelThematic ETF Flow - dars.gov.et
Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus - Sahm
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data - Sahm
Arcus Biosciences (RCUS) Surges 4.88%: Momentum Builds Near ResistanceFactor ETF Flow - dars.gov.et
Arcus Biosciences stock extends recent pullback as technical signals favor stabilization - Traders Union
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Yahoo Finance
RCUSArcus Biosciences Inc Latest SEC Filings - Finviz
Arcus Biosciences stock drops 2.43% as Nature publication highlights kidney cancer research, arcusbio says - Traders Union
Arcus kidney cancer drug shows 12.2-month median survival By Investing.com - Investing.com Nigeria
HIF-2a inhibition with casdatifan (IMAGE) - EurekAlert!
Arcus Biosciences (RCUS) Unveils Promising ARC-20 Study Findings on Casdatifan - GuruFocus
Arcus kidney cancer drug shows 12.2-month median survival - Investing.com
New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan - EurekAlert!
Arcus study links EPO suppression to kidney cancer survival - scanx.trade
Arcus Biosciences (RCUS) Holds Steady Near Support as Biotech Sector Shows Mixed SignalsOBV Divergence - Bölüm Sonu Canavarı
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcus Biosciences Inc (RCUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2.44%
0.02%
자본화:
|
볼륨(24시간):